USA Technologies Inc Surges on Recognized Patent Growth (NASDAQ:USAT), Progenics Pharmaceuticals Inc
01/08/2014

The topic of interest amongst investors surrounding USA Technologies Inc. is its 87 patents granted by the U.S. Patent Office.

Online PR News – 08-January-2014 – Las Vegas, NV – With little investors waiting and alot of profit taking in today's stock market, we would advise you to take a look at USA Technologies Inc. ticker symbol (NASDAQ:USAT). USA Technologies Inc. has surged +11.04% Up 0.23 generating over two point eight million shares in the financial market at $2.31 per share Tuesday January 7, 2014 Real-time: 2:10PM EST. The Company (www.usatech.com) is a leader of wireless, cashless payment and M2M telemetry solutions for self-serve retail industries. The topic of interest amongst investors surrounding USA Technologies Inc. is its 87 patents granted by the U.S. Patent Office. Wall Street analyst are intrigued with USA Technologies newest patent titled Interactive Interface Effectuated Vending U.S. Patent number 8,596,529. This action definitly increase USA Technologies portfolio as they target the self-serve retail market. Another ticker symbol that need not be forgotten is (NASDAQ:PGNX). Progenics Pharmaceuticals, Inc. has surged +5.63% Up 0.31 generating over one point eight million shares in the financial market at $5.78 per share Tuesday January 7, 2014 Real-time: 2:23PM EST. The Company (www.progenics.com) is a oncology company focused on the development of innovative approaches to targeting and treating prostate cancer. The topic of interest amongst investors surrounding Progenics Pharmaceuticals, Inc. is its discoveries from a Phase I study of their Imaging Agent, 1404. Imaging Agent 1404 is a developmental stage radiopharmaceutical imaging agent that is designed to highlight the expression of a distinct protein by cancerous cells. On a different note, take a look at ticker symbol (NASDAQ:IDRA). Idera Pharmaceuticals, Inc. has surged +5.95% Up 0.30 generating over two point one million shares in the financial market at $5.34 per share Tuesday January 7, 2014 Real-time: 2:32PM EST. The Company (www.iderapharma.com) is a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma. The topic of interest amongst investors surrounding Idera Pharmaceuticals, Inc. is its IMO-8400 Phase 1/2 clinical trial enrollment following welcoming of its Investigational New Drug application by the FDA. Read Full Disclaimer at http://crwefinance.com/disclaimer/ Remember: Always do your homework and consult your own financial professional.